Cell and gene therapies have the potential to revolutionize medicine. These groundbreaking treatments use living cells to target and treat disease, and they will have a profound impact on the treatment of cancer, autoimmune diseases, and beyond. However, while scientific advancements in this field are accelerating quickly, manufacturing these treatments has remained costly and slow.
The access gap between patients eligible for cell therapy and those able to receive treatment is overwhelming.
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Foresite Capital Closes $900M Fund Targeting Precision Medicine & Innovation
What You Should Know:
- Foresite Capital, a San Francisco, CA-based healthcare and life sciences investment firm, announced today the successful closing of its sixth fund with a significant $900M in capital commitments. This new fund fuels Foresite's mission to invest in groundbreaking technologies across the healthcare spectrum.
- Fund VI attracted a diverse group of limited partners, including university endowments, charitable foundations, medical institutions, pension funds,
Read More
AlidaBio Secures $7.5M to Optimize Epitranscriptomic Research
What You Should Know:
- Alida Biosciences (AlidaBio), an innovator in epigenomic research tools, proudly announces the successful completion of a $7.5 million Series A funding round. This funding, led by Genoa Ventures with participation from FusionX Ventures and Vertical Venture Partners, is complemented by two ongoing SBIR grants totaling $4 million from The National Human Genome Research Institute
Read More
Komodo Health Unveils Integrated Patient Insurance Dataset for Life Sciences
What You Should Know:
- Komodo Health, a provider of real-world healthcare data and analytics, today announced the launch of Komodo Patient Insurance™ (KPI).
- The new offering delivers the most comprehensive view of patient insurance status available, encompassing over 200 million de-identified U.S. patient lives.
KPI: Unprecedented Depth and Accuracy
KPI surpasses traditional solutions by providing in-depth insights into a patient's pharmacy and medical insurance
Read More
Verily Launches AI-Powered Chronic Care Solution, Lightpath
What You Should Know:
- Verily, Alphabet's precision health subsidiary, today announced Lightpath, a next-generation chronic care solution designed to address the evolving needs of health plans and their members.
- The initial offering, Lightpath Metabolic, focuses on empowering individuals with cardiometabolic conditions to achieve and maintain their health goals. Open enrollment is targeted for early 2026.
Building on Success with Onduo
Lightpath Metabolic leverages the
Read More
Blood Test for Alzheimer’s on the Horizon: ALZpath Licenses pTau217 Antibody to Roche
What You Should Know:
- ALZpath, a leader in Alzheimer's disease diagnostics, announced a licensing agreement with Roche for their innovative pTau217 antibody. This paves the way for a blood test to diagnose Alzheimer's disease using Roche's widely used Elecsys® platform.
- The Roche pTau217 test has already received Breakthrough Device designation from the FDA and will be commercialized as part of a collaboration between Roche and Eli Lilly.
pTau217: A Game Changer in
Read More
Helix Launches Clinico-Genomic Datasets to Accelerate Precision Medicine Drug Discovery
What You Should Know:
- Helix, a leader in population genomics, is launching new datasets designed to empower life science companies in developing precision medicine therapies.
- These comprehensive datasets, built through collaborations with various health systems, provide researchers with a rich resource for drug discovery and development across multiple disease areas.
Unveiling the Power of Clinico-Genomic Data
The datasets offer a unique combination of longitudinal
Read More
Nucleus RadioPharma Secures Investment from AstraZeneca
What You Should Know:
- Nucleus RadioPharma, the world's first comprehensive radiopharmaceutical organization, today announced the closing of an extended Series A funding round with the addition of new investor AstraZeneca.
- The strategic investment bolsters Nucleus' mission to make targeted radiotherapies and theranostics more accessible to patients worldwide.
AstraZeneca Joins Forces with Leading Radiopharmaceutical Innovator
AstraZeneca joins a distinguished group of
Read More
OncoHost and Dana-Farber Partner on Kidney Cancer (RCC) Biomarker Study
What You Should Know:
- OncoHost, a company pioneering personalized medicine approaches for better patient outcomes, announced a collaborative research study with Dana-Farber Cancer Institute, a leading cancer treatment and research center.
- The project aims to identify biomarkers in blood for renal cell carcinoma (RCC), a type of kidney cancer.
The Challenge of Personalized Treatment for RCC:
While immune-checkpoint inhibitor (ICI) therapy has revolutionized RCC treatment,
Read More
IRT: The Unsung Hero of Modern Clinical Trials
The modern landscape of clinical trials is expanding to include hybrid and decentralized approaches to conducting research. As the methods of conducting clinical trials diversify, clinical trial logistics also increase in complexity. In 2024, experts estimate that 50% of clinical trials will be conducted via hybrid or decentralized methods. Though increasing remote access in clinical trials improves convenience, reduces costs and expands diversity, it also presents new challenges in navigating
Read More
